Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Free Cash Flow (2017 - 2021)

Cogent Biosciences (COGT) has 4 years of Free Cash Flow data on record, last reported at -$21.2 million in Q4 2021.

  • For Q4 2021, Free Cash Flow fell 126.46% year-over-year to -$21.2 million; the TTM value through Dec 2021 reached -$60.4 million, down 68.37%, while the annual FY2025 figure was -$266.0 million, 27.66% down from the prior year.
  • Free Cash Flow reached -$21.2 million in Q4 2021 per COGT's latest filing, down from -$15.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$7.9 million in Q2 2018 and bottomed at -$21.2 million in Q4 2021.
  • Average Free Cash Flow over 4 years is -$10.7 million, with a median of -$9.8 million recorded in 2019.
  • Peak YoY movement for Free Cash Flow: surged 31.72% in 2020, then crashed 126.46% in 2021.
  • A 4-year view of Free Cash Flow shows it stood at -$9.0 million in 2018, then grew by 6.23% to -$8.5 million in 2019, then fell by 10.74% to -$9.4 million in 2020, then plummeted by 126.46% to -$21.2 million in 2021.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$21.2 million in Q4 2021, -$15.3 million in Q3 2021, and -$12.5 million in Q2 2021.